Comparison of cost effectiveness between measuring the serum erythropoietin level and reticulocyte count for monitoring thalassemic patients: A note in Thai beta thalassemia/Hb E subjects

Hematology

Volumn 9, Issue 4, 2004, Pages 311-313

  Wiwanitkit, Viroj ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Cost effectiveness; Erythropoiesis; Reticulocyte count; Serum erythropoietin; Thalassemia

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN E;

ARTICLE; BETA THALASSEMIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ERYTHROPOIESIS; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RADIOIMMUNOASSAY; RETICULOCYTE COUNT; SENSITIVITY ANALYSIS; THAILAND;

ANEMIA, IRON-DEFICIENCY; BETA-THALASSEMIA; COST-BENEFIT ANALYSIS; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMOGLOBIN E; HUMANS; MONITORING, PHYSIOLOGIC; RADIOIMMUNOASSAY; RETICULOCYTE COUNT; THAILAND;

EID: 5444225386     PISSN: 10245332     EISSN: None     Source Type: Journal    
DOI: 10.1080/10245330410001714257     Document Type: Article

References (6)

1. Wiwanitkit, V., Paritpokee, N., Bhokaisawan, N., Boonchalermvichian, C., Nuchprayoon, I. and Preechakas, P. (2003) "Monitoring of erythropoietin level in thalassemic patients by radioimmunoassay", Haema 6, 372-375.
2. Flatz, G., Pik, C. and Sringam, S. (1965) "Hemoglobin E and Thalassemia. Their distribution in Thailand", An. Hum. Genet. 29, 151-170.
3. Fucharoen, S. and Winichagoon, P. (1997) "Hemoglobinopathies in Southeast Asia: molecular biology and clinical medicine", Hemoglobin 21, 299-319.
4. Cao, A., Gabutti, V., Galanello, R., Masera, G., Modell, B., Plama, A.D., et al. (1997) "Management protocol for the treatment of thalassemia patients", Nicosia: The Thalassemia International Federation, 30-32.
5. Wiwanitkit, V. (2003) "Is the SLE latex test more appropriate than the LE cell preparation in screening for SLE?", Haema 6, 512-514.
6. Johnston, K. and Buxton, M.J. (1999) "Assessing the cost of health care technologies in clinical trial", Health Technol. Assess. 3, 3-9.